Lonza Expands its Microbial Manufacturing Facility in Switzerland
The expansion will involve using the facilities’ existing central utilities and labs to supplement its small-scale and large-scale assets.
On August 4, 2020, Lonza announced it is expanding its microbial manufacturing facility in Visp, Switzerland, to meet the needs of its extended partnership with Servier, an independent international pharmaceutical company.
According to a Lonza press release, the expansion will involve using the facilities’ existing central utilities and labs to supplement its small-scale and large-scale assets. The updated facility is set to be operational in the second half of 2022 and Lonza will add 100 new staff members to its microbial team.
“By building on our current microbial capabilities, we will be able to continue our long-standing support for Servier as they look to expand access for patients,” said Jean-Christoph Hyvert, chief commercial officer, Lonza, in the press release. “We see a clear role for microbial technology as new medicines evolve and we are investing in key enablers, including expression technology and manufacturing assets.”
Since 2009, Lonza has produced Servier’s anti-cancer chemotherapy drug, L-asparaginase. The extension of the companies’ long-standing partnership will now give Servier the additional capacity needed to provide treatment to more patients with acute lymphoblastic leukemia (ALL), the press release said.
"We are extremely pleased to already have been collaborating with Lonza for the production of L-asparaginase, the active pharmaceutical ingredient for our ALL therapeutic regimens, allowing us to quickly provide for patients we serve,” said Pierre Venesque, executive vice-president, Industry, Servier, in the press release. “Lonza’s drug manufacturing experience [and] infrastructure is important to this partnership and ensures the timely supply of these therapeutics.”
Source: Lonza
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.
